# Cumulative Pathway Load Safety — Product Strategy Guide
## For DT and Wil | April 2026

---

## THE CORE TENSION

Bioweave exists in a paradox:

1. **We must be effective enough** to justify the effort of DNA testing, blood work, and a monthly subscription. If we recommend 3 vitamins that people could figure out themselves, there's no value proposition.

2. **We must be safer than everyone else** because our entire pitch is "generic supplements cause harm — we're smarter." If we cause harm too, we're worse than IM8 because we PROMISED to be better.

3. **The more sophisticated the engine gets, the more compounds it recommends, and the higher the risk of cumulative pathway conflicts.** Precision creates its own danger.

This isn't a bug — it's THE fundamental product design challenge. The system that solves this IS the product.

---

## WHAT ACTUALLY HAPPENED WITH DT (honest assessment)

DT took L-theanine, taurine, magnesium glycinate, and Reaptan simultaneously. All four enhance GABA/inhibitory pathways. He experienced dizziness, brain fog, derealization, and panic for approximately a month. When he stopped theanine and taurine, symptoms cleared within days.

**This is strongly suggestive but not proven.** It could have been:
- Cumulative GABA over-inhibition (Ora's hypothesis — most likely)
- Anxiety disorder exacerbation (DT's initial assumption)
- Blood pressure medication interaction
- Something else entirely

**What matters for the product:** Whether this specific case was definitively pathway overload or not, the PRINCIPLE is sound — stacking multiple compounds that affect the same pathway is a known pharmacological risk. Bioweave needs a system that catches this.

---

## THE PRODUCT DESIGN FRAMEWORK

### Three Safety Layers (in order of evaluation)

**Layer 1: Gene-Compound Gate (already built)**
- The Pharmacogenomic Safety Index
- Binary: this compound is safe/unsafe for your genotype
- Example: methylcobalamin is contraindicated for COMT slow + MTHFR compound het
- This catches the most dangerous individual conflicts
- Status: Wil has a working prototype

**Layer 2: Drug-Supplement Interaction Check (standard)**
- Cross-reference every recommended compound against the user's medications
- Use established databases (DrugBank, Natural Medicines Database)
- Binary: this combination is flagged/not flagged
- Status: Standard pharmacology — well-established, needs implementation

**Layer 3: Cumulative Pathway Load Model (NEW — the moat)**
- Map every compound to the biological pathways it affects
- Calculate the TOTAL load on each pathway from the full stack
- Flag when cumulative load on any pathway exceeds a safe threshold
- This is what nobody else does
- Status: Needs to be designed and built

### How Layer 3 Works (for Wil)

**Step 1: Pathway Mapping**
Create a database mapping compounds to pathways with direction and magnitude:

```
Compound → Pathway → Direction → Magnitude (0-1)

L-Theanine → GABA → ↑ → 0.6
L-Theanine → Glutamate → ↓ → 0.5
Taurine → GABA → ↑ → 0.5
Magnesium → GABA → ↑ → 0.3
Reaptan → CNS inhibition → ↑ → 0.3
Methylfolate → Methylation → ↑ → 0.7
SAMe → Methylation → ↑ → 0.6
Methyl-B12 → Methylation → ↑ → 0.5
```

**Step 2: Stack Calculation**
For any proposed stack, sum the pathway loads:

```
Proposed stack: L-Theanine + Taurine + Magnesium + Reaptan

GABA pathway load = 0.6 + 0.5 + 0.3 + 0.3 = 1.7
Threshold for GABA = 1.0

⚠️ ALERT: GABA pathway load exceeds safe threshold (1.7 > 1.0)
```

**Step 3: Genetic Modifier**
Adjust thresholds based on genetics:
- COMT slow/intermediate → LOWER threshold for catecholamine/GABA pathways
- MTHFR variants → LOWER threshold for methylation pathway
- CYP metaboliser status → adjust thresholds for relevant pathways

```
DT: COMT AG (intermediate) → GABA threshold reduced from 1.0 to 0.7

GABA load 1.7 >> adjusted threshold 0.7

🔴 CRITICAL: Remove at least one GABA-enhancing compound
Recommendation: Keep magnesium (needed for other reasons), remove theanine OR taurine, not both
```

**Step 4: Optimisation**
When a pathway conflict is detected, the system should:
1. Identify which compound contributes MOST to the overloaded pathway
2. Check if removing it resolves the conflict
3. Check if a SUBSTITUTE exists that achieves the same clinical goal via a DIFFERENT pathway
4. Present the doctor with options, not just a block

---

## THE KEY PATHWAYS TO MODEL (Priority Order)

### High Priority (known stacking risks)
1. **GABAergic pathway** — theanine, taurine, magnesium, ashwagandha, valerian, GABA itself, glycine
2. **Methylation pathway** — methylfolate, methyl-B12, SAMe, TMG, choline, betaine
3. **Serotonergic pathway** — 5-HTP, tryptophan, St John's Wort, SAMe (serotonin syndrome risk)
4. **Dopaminergic pathway** — tyrosine, mucuna, SAMe, methylated B vitamins
5. **Anticoagulant pathway** — omega-3, vitamin E, ginkgo, turmeric/curcumin
6. **Histamine pathway** — certain probiotic strains, histidine, DAO inhibitors

### Medium Priority
7. **Iron absorption pathway** — iron, vitamin C (enhancer), calcium (inhibitor), zinc (competitor)
8. **Thyroid pathway** — iodine, selenium, zinc, tyrosine, goitrogens
9. **Blood pressure pathway** — CoQ10, magnesium, potassium, Reaptan interaction
10. **Cortisol/HPA axis** — ashwagandha, phosphatidylserine, rhodiola, holy basil

### Lower Priority (but still needed)
11. **Fat-soluble vitamin accumulation** — A, D, E, K (toxicity at high doses)
12. **Mineral competition** — zinc/copper balance, calcium/magnesium ratio, iron/zinc competition
13. **CYP enzyme loading** — compounds that inhibit/induce the same CYP enzymes as medications

---

## HOW THIS BECOMES THE PRODUCT PROPOSITION

### The Pitch (for customers)
"Other companies recommend supplements one at a time. Bioweave models how your ENTIRE stack works together — catching conflicts that no individual recommendation would reveal."

### The Pitch (for investors/partners like Radek)
"We've built three safety layers. The first checks your genes against each compound. The second checks drug interactions. The third — which nobody else has — models the cumulative load on your biological pathways and prevents over-stimulation of any single system. This is the moat."

### The Pitch (for doctors)
"Every formulation comes with a pathway load report showing the cumulative effect on each biological system. You can see at a glance whether any pathway is being over-stimulated. This gives you clinical confidence to sign off."

### How it addresses the core tension:
- **Effective:** We recommend MORE compounds than generic stacks — but each one is justified by YOUR biology
- **Safe:** We model the cumulative effect, catching conflicts that even good doctors miss
- **Worth the effort:** "You can't do this yourself. No practitioner does this. Only Bioweave models your complete pathway load."

---

## PRACTICAL NEXT STEPS FOR WIL

### Phase 1: Build the Pathway Database (2-4 weeks)
1. Create a structured database: `compound_id → pathway_id → direction → magnitude → evidence_source`
2. Start with the 69 compounds in our library
3. Map each to all known pathway effects
4. Sources: DrugBank, PubChem, Natural Medicines Database, published reviews
5. Store as structured data (JSON or Postgres) — this becomes core IP

### Phase 2: Build the Calculator (1-2 weeks)
1. For any proposed stack, sum pathway loads
2. Apply genetic modifiers to thresholds
3. Apply medication interactions
4. Output: pathway load report (like a bar chart — green/amber/red for each pathway)

### Phase 3: Build the Resolver (2-4 weeks)
1. When a conflict is detected, identify substitution options
2. "Remove theanine, add [alternative] to achieve the same goal via a different pathway"
3. Present to the doctor as options with rationale
4. This is the INTELLIGENCE layer — not just flagging, but solving

### Phase 4: Integrate into the Recommendation Engine
1. After the AI Medical Board generates a protocol, BEFORE the doctor sees it:
   - Run Layer 1 (gene-compound gate)
   - Run Layer 2 (drug interaction check)
   - Run Layer 3 (cumulative pathway load)
2. If any flag is raised, the system resolves it automatically
3. The doctor sees a clean protocol with a pathway load report attached

---

## THE COMPETITIVE POSITION

| Company | Gene Check | Drug Check | Pathway Load |
|---------|-----------|-----------|-------------|
| IM8 | ✗ | ✗ | ✗ |
| Blueprint | ✗ | Partial | ✗ |
| AgeMate | ✗ | ✗ | ✗ |
| Superpower | ✗ | ✗ | ✗ |
| Function | ✗ | ✗ | ✗ |
| Generic practitioners | Rare | Manual | ✗ |
| **Bioweave** | **✓** | **✓** | **✓** |

Nobody does all three. The pathway load model is genuinely novel — it could be a publishable paper, a patent, and the technical foundation of the entire business.

---

## WHITE PAPER OUTLINE (for publication)

Title: "Cumulative Pathway Load Modelling: A Safety Framework for Personalised Supplement Protocols"

1. Introduction — the stacking problem in personalised nutrition
2. Case study — GABA pathway overload (anonymised DT case)
3. Methodology — pathway mapping, load calculation, genetic modifiers
4. The three-layer safety architecture
5. Implementation in an AI recommendation engine
6. Discussion — limitations, future research
7. Conclusion — call for industry adoption

This could be submitted to: Nutrients (MDPI), Frontiers in Nutrition, or British Journal of Nutrition. Publishing this establishes Bioweave as the thought leader on supplement safety.

---

## DT's QUESTION ANSWERED

"How do we make this effective enough to be worth the effort, while being safer than everyone else?"

**Answer:** The pathway load model IS the answer. It lets us recommend MORE compounds with HIGHER confidence, because we can prove the stack is safe as a SYSTEM, not just as individual ingredients. The doctor sees a pathway load report. The customer sees "rigorously tested for YOUR biology." The investor sees a moat that nobody else has.

The value proposition isn't "we give you fewer pills." It's "we give you the RIGHT pills, AND we prove they work together safely." That's worth getting a blood test for.